DINAMIQS, which became part of the Siegfried Group in Zofingen in the Swiss canton of Aargau in 2023, has inaugurated a new research and development laboratory in the Bio-Technopark Schlieren-Zurich. It features new “state-of-the-art” laboratory capacities housing “leading technologies” in the field of viral vector process development and manufacturing, according to a statement from Siegfried. The parent company describes this as an important step on its path to further strengthen its biologics offering, “particularly in the fast-growing cell and gene therapy market”.
The new laboratory's pilot-scale equipment will reportedly enable DINAMIQS to provide clinical viral vector development, analytical and manufacturing services. Currently under construction, the lab is an integral part of the company’s 2,500 square-meter cGMP manufacturing facility and is set to be operational by the end of 2025. According to the statement, it will host a capacity of up to 1,000 liters for the production of viral vectors for research and development, clinical trials and commercial use.
For Siegfried CEO Marcel Imwinkelried, the new lab facility marks “a key milestone in DINAMIQS’ journey to becoming the leading CDMO in the cell and gene therapy space”. DINAMIQS CEO Martin Kessler emphasizes “the importance of leading process development and analytics for the success of viral vector projects”, saying that “this is why we have expanded our Swiss labs significantly. From the optimization of genomes to GMP scale-up our clients now get everything out of one hand.” ce/mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space